Suppr超能文献

根治性放化疗治疗口咽鳞状细胞癌患者的淋巴结融合与预后的关系。

Prognostic impact of matted lymphadenopathy in patients with oropharyngeal squamous cell carcinoma treated with definitive chemoradiotherapy.

机构信息

Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, United States.

Department of Radiology, UT Southwestern Medical Center, Dallas, TX, United States.

出版信息

Oral Oncol. 2021 Dec;123:105623. doi: 10.1016/j.oraloncology.2021.105623. Epub 2021 Nov 19.

Abstract

OBJECTIVE

To determine whether cervical matted lymphadenopathy (ML) is associated with outcomes in patients with oropharyngeal squamous cell carcinoma (OPSCC) treated with definitive chemoradiotherapy (CRT).

MATERIALS AND METHODS

OPSCC patients treated at our institution with CRT were included (n = 417). ML was defined by three adjacent nodes without an intervening fat plane. Patients were stratified into favorable OPSCC (p16 + with ≤ 10 pack-years smoking history) or unfavorable OPSCC (p16- and/or > 10 pack years). Primary outcomes were overall survival (OS) and progression-free survival (PFS) and the cumulative incidences of regional recurrence (RR) and distant metastasis (DM).

RESULTS

The median follow-up time for the surviving cohort was 49.9 months. In favorable OPSCC (n = 220), there were no significant associations between ML and any outcome. In unfavorable OPSCC (n = 197), ML had a significant negative impact on OS and PFS, with 3-year OS for patients without and with matted nodes at 74% and 56% (HR, 1.61, 95% CI 1.01-2.58). On multivariable Cox regression, patients with ML experienced significantly worsened OS (HR 1.65, 95% CI 1.03-2.65) and PFS (HR 1.94, 95% CI 1.28-2.93). The cumulative incidence of DM was also higher with ML (31% vs. 9%, adjusted HR 3.3, 95% CI 1.71-6.48).

CONCLUSION

ML carries no prognostic importance in patients with favorable OPSCC. However, ML portends significantly worse outcomes in individuals with HPV-negative disease or a significant smoking history. Thus, ML may help risk-stratify this latter population for treatment intensification, but does not seem to be a contraindication for treatment de-escalation in the former.

摘要

目的

确定颈淋巴结融合(ML)是否与接受根治性放化疗(CRT)治疗的口咽鳞癌(OPSCC)患者的结局相关。

材料和方法

纳入在我院接受 CRT 治疗的 OPSCC 患者(n=417)。ML 通过三个无间隔脂肪平面的相邻淋巴结定义。患者分为有利口咽鳞癌(p16+,吸烟史≤10 包年)或不利口咽鳞癌(p16-,和/或吸烟史>10 包年)。主要结局是总生存(OS)和无进展生存(PFS),区域性复发(RR)和远处转移(DM)的累积发生率。

结果

幸存队列的中位随访时间为 49.9 个月。在有利口咽鳞癌(n=220)中,ML 与任何结局均无显著关联。在不利口咽鳞癌(n=197)中,ML 对 OS 和 PFS 有显著的负面影响,无 ML 组和有 ML 组的 3 年 OS 分别为 74%和 56%(HR,1.61,95%CI 1.01-2.58)。多变量 Cox 回归分析显示,有 ML 的患者 OS(HR 1.65,95%CI 1.03-2.65)和 PFS(HR 1.94,95%CI 1.28-2.93)明显恶化。有 ML 组的 DM 累积发生率也更高(31% vs. 9%,调整后的 HR 3.3,95%CI 1.71-6.48)。

结论

ML 在有利口咽鳞癌患者中无预后意义。然而,ML 在 HPV 阴性疾病或大量吸烟史患者中预示着更差的结局。因此,ML 可能有助于对这部分人群进行风险分层以加强治疗,但似乎不是对前者进行治疗降级的禁忌症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验